Premium
Treatment of Helicobacter pylori Infection 2010
Author(s) -
O’Connor Anthony,
Gisbert Javier P.,
McNamara Deirdre,
O’Morain Colm
Publication year - 2010
Publication title -
helicobacter
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.206
H-Index - 79
eISSN - 1523-5378
pISSN - 1083-4389
DOI - 10.1111/j.1523-5378.2010.00774.x
Subject(s) - rifabutin , medicine , helicobacter pylori , levofloxacin , clarithromycin , intensive care medicine , patient compliance , antibiotic resistance , antibiotics , biology , microbiology and biotechnology , family medicine
It is accepted that the success of Helicobacter pylori eradication treatment using standard triple therapy is declining. Resistance, particularly to clarithromycin, has been shown in numerous countries to be rising to a level where the use of standard triple therapy in its current form may no longer be justified. The two major factors influencing resistance are prior exposure to the antibiotic and compliance with therapy. Regimes based on bismuth and levofloxacin, which had previously been mainly second‐line options, are now emerging as superior first‐line options. Trials of sequential and concomitant therapies are also showing the usefulness of these treatments in different populations. Options for third and subsequent line therapies include furazolidone and rifabutin‐based regimes. Susceptibility testing should be performed to maintain accurate data on resistance levels, and has also clinical utility in difficult to eradicate cases. None of these, however, will be successful unless compliance is improved upon. If compliance is assured and eradication confirmation pursued, it has been repeatedly illustrated that near full eradication is achievable.